Amy Paterson, Medical Analyst at GlobalData states, “Medtronic’s Sphere-9 launched at a lower price than Boston Scientific’s ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

From new leadership to product launches, here are five key updates from spine and orthopedic devicemakers since Jan. 15.

J&J’s 2025 results will be the launching point for its guidance of 5%-7% revenue growth for 2025-30, which is still well ...

All participants will be in a listen-only mode until the question-and-answer session of the conference. This call is being ...

Johnson & Johnson (J&J) MedTech has reported a 4.8% growth in global sales in 2024, though it expects its 2025 outlook to ...

Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the ...

CEO Joaquin Duato said the company is positioned for sustained growth in coming years even as competition batters Stelara, ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

The pharmaceutical company’s latest earnings exceeded Wall Street’s expectations as it braces for one of its top-selling ...